Interestingly, we observed a similar immunomodulatory effect in RR−EAE mice after treatment with the other S100B inhibitor PTM [13], which also ameliorates clinical scores and pathological parameters in this in vivo MS model. Here, S100B is linked to myeloid sarcoma.